Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2012. The report specifically details a share repurchase transaction executed on September 18, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,400,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,447.5 pence per share; lowest price paid was 1,430 pence per share.
- Treasury Holdings (Settled): 517,915,427 shares (9.46% of total issued share capital).
- Treasury Holdings (Including Unsettled): 522,665,427 shares (10.55% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,954,979,115 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,400,000 shares. This transaction increased the proportion of shares held in Treasury from the prior level to 9.46% of issued capital (or 10.55% of voting rights including unsettled shares). No other operational or financial changes are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding share repurchases.
Key Facts for Investor Verification
- Verify the total cost of the 1,400,000 share repurchase against the reported price range (1,430 to 1,447.5 pence).
- Confirm the updated total voting rights denominator (4,954,979,115 shares) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Monitor the settlement status of the shares to confirm the final Treasury holding percentage stabilizes at 9.46% of issued capital.